4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
11.60
+0.08 (0.69%)
At close: Jun 26, 2026, 4:00 PM EDT
11.37
-0.23 (-1.98%)
After-hours: Jun 26, 2026, 7:43 PM EDT
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 29.5, with a low estimate of 21 and a high estimate of 36. The average target predicts an increase of 154.31% from the current stock price of 11.60.
Analyst Consensus: Buy
* Price targets were last updated on May 11, 2026.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $36 | Buy | Reiterates | $36 | +210.34% | May 11, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $26 | Buy | Reiterates | $26 | +124.14% | May 8, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $35 | Buy | Maintains | $35 | +201.72% | May 8, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $38 → $33 | Buy | Maintains | $38 → $33 | +184.48% | May 8, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $29 | Buy | Reiterates | $29 | +150.00% | May 8, 2026 |
Financial Forecast
Revenue This Year
11.60M
from 85.21M
Decreased by -86.39%
Revenue Next Year
17.51M
from 11.60M
Increased by 50.93%
EPS This Year
-3.92
from -2.42
EPS Next Year
-3.72
from -3.92
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 30.0M | 38.3M | |
| Avg | 11.6M | 17.5M | |
| Low | 3.0M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -64.8% | 230.2% | |
| Avg | -86.4% | 50.9% | |
| Low | -96.5% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -3.92 | -3.72 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.